Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma.

ABSTRACT:

Background

There is a lack of biomarkers to identify glioblastoma (GBM) patients who may benefit from specific salvage therapies, such as the anti-angiogenic agent bevacizumab. We hypothesized that circulating blood counts may serve as biomarkers for treatment response and clinical outcomes.

Methods

Complete blood counts, clinical data, and radiographic information were collected retrospectively from 84 recurrent GBM patients receiving bevacizumab (10 mg/kg every 2 weeks). Significant biomarkers were categorized into quartiles and the association with clinical outcomes was assessed using the Kaplan-Meier method.

Results

The median treatment duration and survival on bevacizumab (OS-A) was 88 and 192 days, respectively. On multivariate analysis, MGMT promoter met

SUBMITTER: Vaios EJ 

PROVIDER: S-EPMC7212859 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature